Novo Nordisk A/S – Share repurchase programme
16 Oktober 2023 - 2:09PM
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 16 October 2023 – On 10
August 2023, Novo Nordisk initiated a share repurchase programme in
accordance with Article 5 of Regulation No 596/2014 of the European
Parliament and Council of 16 April 2014 (MAR) and the Commission
Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe
Harbour Rules"). This programme is part of the overall share
repurchase programme of up to DKK 30 billion to be executed during
a 12-month period beginning 1 February 2023.
Under the programme initiated 10 August 2023, Novo Nordisk will
repurchase B shares for an amount up to DKK 5.7 billion in the
period from 10 August 2023 to 31 October 2023.
Since the announcement 09 October 2023, the following
transactions have been made:
|
|
Number of B shares (of DKK 0.10) |
Average purchase price |
Transaction value, DKK |
|
Accumulated, last announcement |
6,258,162 |
|
4,054,258,168 |
| 09 October
2023 |
150,000 |
649.47 |
97,420,869 |
| 10 October
2023 |
150,000 |
646.50 |
96,975,403 |
| 11 October
2023 |
150,000 |
673.34 |
101,000,768 |
| 12 October
2023 |
145,000 |
696.74 |
101,027,220 |
| 13 October
2023 |
140,000 |
702.22 |
98,310,605 |
|
Accumulated under the programme |
6,993,162 |
|
4,548,993,033 |
The details for each transaction made under the share repurchase
programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of
39,486,846 B shares of DKK 0.10 as treasury shares, corresponding
to 0.9% of the share capital. The total amount of A and B shares of
DKK 0.10 in the company is 4,510,000,000 including treasury
shares.
Novo Nordisk expects to repurchase B shares for an amount up to
DKK 30 billion during a 12-month period beginning 1 February 2023.
As of 13 October 2023, Novo Nordisk has since 1 February 2023
repurchased a total of 35,430,324 B shares of DKK 0.10 at an
average share price of DKK 559.92 per B share of DKK 0.10 equal to
a transaction value of DKK 19,838,223,618.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat serious chronic diseases, built upon our heritage in
diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 59,000 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Instagram, X,
LinkedIn and YouTube.
Contacts for further information
|
Media: |
|
| Ambre
James-Brown +45 3079 9289abmo@novonordisk.com |
Elizabeth
DeLuca (US)+1 609 580 9868edel@novonordisk.com |
|
Investors: |
|
| Daniel
Muusmann Bohsen+45 3075 2175 dabo@novonordisk.com |
Jacob
Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com |
| David
Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
Mark
Joseph Root (US) +1 848 213 3219mjhr@novonordisk.com |
| Sina
Meyer +45 3075 6656 azey@novonordisk.com |
Frederik
Taylor Pitter +45 3075 8259 fptr@novonordisk.com |
Company announcement No 65 / 2023
- 20231016 - Share-repurchase
- 20231016 - transaction details
Novo Nordisk (TG:NOVC)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
Von Nov 2023 bis Nov 2024
